Rahul M. Kohli, M.D, Ph.D
Assistant Professor of Medicine
Department: Medicine
Graduate Group Affiliations
Contact information
502B Johnson Pavilion
Division of Infectious Disease, Department of Medicine
3610 Hamilton Walk
Philadelphia, PA 19104-6073
Division of Infectious Disease, Department of Medicine
3610 Hamilton Walk
Philadelphia, PA 19104-6073
Office: 215-573-7523
Fax: 215-349-5111
Fax: 215-349-5111
Email:
rkohli@upenn.edu
rkohli@upenn.edu
Publications
Education:
B.S. (Biochemistry)
University of Michigan, 1998.
M.D.
Harvard Medical School, 2004.
Ph.D. (Biochem & Mol Pharm, Advisor: Christopher T. Walsh)
Harvard Medical School, 2004.
Intern (Internal Medicine)
Hospital of the University of Pennsylvania, 2005.
Resident (Internal Medicine)
Hospital of the University of Pennsylvania, 2006.
Fellow (Pharm and Mol Science, Advisor: James T. Stivers)
Johns Hopkins University School of Medicine, 2010.
Fellow (Infectious Diseases)
Johns Hopkins Hospital, 2010.
Permanent linkB.S. (Biochemistry)
University of Michigan, 1998.
M.D.
Harvard Medical School, 2004.
Ph.D. (Biochem & Mol Pharm, Advisor: Christopher T. Walsh)
Harvard Medical School, 2004.
Intern (Internal Medicine)
Hospital of the University of Pennsylvania, 2005.
Resident (Internal Medicine)
Hospital of the University of Pennsylvania, 2006.
Fellow (Pharm and Mol Science, Advisor: James T. Stivers)
Johns Hopkins University School of Medicine, 2010.
Fellow (Infectious Diseases)
Johns Hopkins Hospital, 2010.
Description of Research Expertise
Our laboratory focuses on the enzymatic generation of genomic diversity. We utilize a broad array of approaches, including biochemical characterization of enzyme mechanisms, chemical synthesis of enzyme probes, and biological assays spanning immunology and virology to study this central tactic in the constant battle between our immune system and pathogens.From the host immune perspective, the generation of genomic diversity is used as both a defensive and an offensive weapon. On the one hand, host mutator enzymes such as Activation-Induced Cytidine Deaminase (AID) seed diversity in the adaptive immune system by introducing targeted mutations into the immunoglobulin locus that result in high affinity antibodies (somatic hypermutation) or altered isotypes (class switch recombination). Conversely, related deaminases of the innate immune system can directly attack retroviral threats by garbling the pathogen genome through mutation, as accomplished by the deaminase APOBEC3G, which restricts infection with HIV. Immune mutator enzymes, however, also pose a risk to the host, as overexpression or dysregulation have been associated with oncogenesis.
From the pathogen perspective, alteration in key antigenic determinants at a rate that outpaces immune responses is a potent means for evasion. Further, rapid mutation may allow for the development of resistance to antimicrobials.
Our research program aims to understand the enzymatic basis for diversity generation in the immune system and pathogens. We further aim to harness these diversity-generating systems for directed evolution and to chemically perturb these pathways to impede pathogen escape or prevent the neoplastic transformations that can result from genomic mutation.
Accepting Rotation Students.
Projects/Goals of interest to the laboratory include:
1. Decipher the molecular basis for deamination by AID/APOBEC enzymes and perturb deaminase immunological functions.
Members of the AID/APOBEC family are linked by the ability to bind nucleic acids, but distinguished from one another by targeting distinctions, at a global level (host vs. pathogen genome) and at a local level (targeting distinct DNA hotspots for deamination). We use a combination of chemical perturbation of substrates with site-directed mutagenesis to decipher the molecular determinants of deamination and targeting. We further posit that mechanism based chemical probes will offer needed insight into polynucleotide deaminase function and yield lead compounds for inhibition of potentially oncogenic AID/APOBEC activity. We aim to translate biochemical insights into immunologic and virologic studies that can reveal the enzymatic roles in HIV restriction, antibody diversity and unwanted chromosomal translocations.
2. Target pathogen pathways that promote evolution and resistance.
Pathogens diversity allows for escape from immune pressures or resistance to antimicrobials. Diversity can be introduced by multiple means in pathogens: error prone replication by HIV reverse transcriptase, activation of the SOS pathways in bacteria and antigenic variation via gene conversion in trypanosomes represent a few remarkable examples. These pathways share a common thread of using DNA repair or replication enzymes in error prone manners and either revealing preexisting hidden genetic variations or newly introducing mutations. Targeting the enzymes that allow for the emergence of pathogen diversity offers an appealing, novel target to prevent the emergence of resistance and attenuate pathogen virulence. We initially aim to characterize the enzymes involved in the SOS pathway in Pseudomonas and develop small molecule inhibitors of these enzymes for evaluation as anti-infective agents with the ability to prevent the emergence of drug resistance.
Selected Publications
Kohli RM: The Chemistry of a Dynamic Genome. Nature Chem Biol 6(12): 866-868, 2010.Kohli RM, Maul RW, Guminski AF, McClure RL, Gajula KS, Saribasak H, McMahon MA, Siliciano RF, Gearhart PJ, Stivers JT.: Local sequence targeting in the AID/APOBEC family differentially impacts retroviral restriction and antibody diversification. J Biol Chem 285(52): 40956-40964, 2010.
Kohli RM, Abrams SR, Gajula KS, Maul RW, Gearhart PJ, Stivers JT: A portable hotspot recognition loop transfers sequence preferences from APOBEC family members to activation-induced cytidine deaminase. J Biol Chem 284: 22898-22904, 2009.
McMahon MA, Siliciano JD, Lai L, Liu JO, Stivers JT, Siliciano RF, Kohli RM: The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation. J Biol Chem 283: 31289-31293, 2008.
Kohli RM, Walsh CT: Enzymology of acyl chain macrocyclization in natural product biosynthesis. Chem Commun 7: 297-307, 2003.
Kohli RM, Burke MD, Tao J, Walsh CT: Chemoenzymatic route to macrocyclic hybrid peptide/polyketide-like molecules. J Am Chem Soc 125: 7160-7161, 2003.
Kohli RM, Walsh CT, Burkart MD: Biomimetic synthesis and optimization of cyclic peptide antibiotics. Nature 418: 658-661, 2002.
Kohli RM, Trauger JW, Schwarzer D, Marahiel MA, Walsh CT: Generality of peptide cyclization catalyzed by isolated thioesterase domains of nonribosomal peptide synthetases. Biochemistry 40: 7099-7108, 2001.
Kohli RM, Takagi J, Walsh CT: The thioesterase domain from a nonribosomal peptide synthetase as a cyclization catalyst for integrin binding peptides. Proc Natl Acad Sci USA 99: 1247-1252, 2002.
Trauger JW, Kohli RM, Mootz HD, Marahiel MA, Walsh CT: Peptide cyclization catalysed by the thioesterase domain of tyrocidine synthetase. Nature 407: 215-218, 2000.

